Topical delgocitinib, a pan-Janus kinase inhibitor, was found to be well tolerated and effective in reducing the severity and symptoms of moderate to severe chronic hand eczema in two phase 3 trials involving nearly 1,000 patients. The primary endpoint of achieving treatment success was met in a higher number of patients receiving delgocitinib compared to those receiving vehicle. Delgocitinib also significantly improved itch and pain scores, as well as overall eczema severity scores. Adverse event rates were similar between the treatment and vehicle groups, with most events being mild to moderate. The study authors concluded that delgocitinib cream is an efficacious and safe treatment for chronic hand eczema.
Source link
Delgocitinib Effective for Hand Eczema in Phase 3 Studies
